IL15 and neoplasm: Without accessory transgenes (CCL5 and IL-15), high doses of unarmed oncolytic-adenovirus controlled tumour growth without the need for CAR T cells, but synergised with CAR T cells at lower doses, with modest effects on CAR T cell persistence noted.